Navigation Links
Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Date:11/8/2013

GAITHERSBURG, Md., Nov. 8, 2013 /PRNewswire-iReach/ -- Panacea Pharmaceuticals, Inc. presents three papers regarding its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD held November 8-10, 2013.  The three papers are titled:

Design, Development and Production of Nano-Particle-Based Anticancer Vaccine Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH)

Immunogenicity of a Lambda Phage-Based Anti-Cancer Vaccine Targeting HAAH

Inhibition of Tumor Growth in vivo by a Nanoparticle-Based Therapeutic Cancer Vaccine Targeting HAAH

(Photo: http://photos.prnewswire.com/prnh/20131108/MN13284)

Panacea has chosen to target the HAAH molecule for its proprietary therapeutic cancer vaccine because HAAH is expressed on cancer cells and not on non-cancer cells and its function is consistent with the etiology of cancer, i.e., is associated with growth, motility and invasiveness of cancer cells.  Monoclonal antibodies to HAAH have proven to have efficacy in both in vitro and in vivo tumor models.  HAAH is, however, an embryonic antigen, and as such, presents self-antigen tolerance.  The present vaccine entity is designed to overcome this tolerance by altering the presentation of the antigen and by providing an immunostimulant.  The nanoparticle is neutralized bacteriophage construct containing portions of HAAH, is easy to produce and is generally regarded as safe.  The nanoparticle vaccine carries 200-300 copies of HAAH fragments of approximately 25 kDa molecular weight on its surface.  The nanoparticle vaccine also contains DNA fragments that present the phage CpG motif to activate the MHC class II pathway.  We have engineered and manufactured the nanoparticle vaccine to meet FDA requirements for human use.

The nanoparticle therapeutic cancer vaccine targeting HAAH is clearly immunogenic in mice despite the high degree of homology to the human protein that makes the AAH resemble a self-antigen.  All three HAAH-lambda constructs were immunogenic and the antibody response was dose-dependent.  The nanoparticle therapeutic cancer vaccine targeting HAAH is effective in inhibition of tumor growth in mice under various conditions.  Each of the three constructs can inhibit tumor growth.  The vaccine can slow the growth of tumors prophylactically or by treatment simultaneous with or subsequent to establishment of solid tumors.

"We are excited to report that the nanoparticle-based therapeutic cancer vaccine targeting HAAH can be manufactured readily and is effective in tumor models", said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.  "The HAAH phage constructs are now being developed as clinical candidate vaccines and we are taking all the steps to prepare for an IND submission to FDA", said Steven Fuller, Ph.D., COO of Panacea.

Media Contact: Hossein Ghanbari, Panacea Pharmaceuticals, Inc., 240-305-4601, hag@panaceapharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
2. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
3. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
4. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
5. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
6. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
7. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Cumberland Pharmaceuticals Reports Third Quarter Financial Results
10. Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
11. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):